Implication for health policy/practice/research/ medical education
Sclerostin is a Wnt signaling pathway antagonist which leads to a negative regulation of bone formation by inhibiting proliferation and differentiation of osteoblasts. It can be assumed that, sclerostin which is expressed in osteocytes and some chondrocytes is able to inhibit bone formation by osteoblasts. Additionally, sclerostin prevents osteoblast proliferation and differentiation enhancing their apoptosis through canonical Wnt signaling blocking. Since chronic kidney disease-metabolic bone disorder induces cardiovascular disease and mortality in chronic kidney disease patients, the association of serum sclerostin levels and the future outcome may become a crucial entity.
Please cite this paper as: Nasri H. An update on sclerostin and kidney. J Parathyr Dis. 2016;4(1):1-2.